The study's lead author said the findings may show something similar to the "obesity paradox," where high-risk patients fare better than expected due to frequent follow-up by physicians.
A study being presented this week at the American College of Cardiology (ACC) 66th Scientific Session finds that for some patients, having high systolic blood pressure does not lead to a higher risk of death, even though there are important implications for managed care.
The study, involving the Gulf-CARE registry and funded by Servier, a French pharmaceutical company, examined health records of 2492 patients with type 2 diabetes (T2D) who were among 5005 hospitalized with acute heart failure in 7 Middle Eastern countries: Oman, Saudia Arabia, Yemen, Kuwait, Qatar, Bahrain, and United Arab Emirates.
Results show that patients with both T2D and acute heart failure had a lower risk of death—but a higher risk of heart-related hospitalization—if they had high systolic blood pressure when discharged from the hospital, when compared with those with normal blood pressure. Although this study does not involve US health records, it’s worth looking at the results given that Medicare and many commercial health plans in the United States closely scrutinize 30-day readmission rates, and hospitals can face penalties for failing to meet targets in this area.
A statement from the ACC said this was the first study to examine blood pressure and health outcomes among people with T2D and among those with heart failure. Those with systolic blood pressure above 150 mmHg were 45% less likely to die, but 47% more likely to be hospitalized for heart failure during a 12-month follow up period. A normal systolic blood pressure reading should be lower than 140 mmHg in patients with diabetes, and lower than 130 mmHg in everyone else.
However, patients suffering from both conditions may have a “distinct pathophysiology of the heart and may benefit from different guidelines,” said lead study author Charbel Abi Khalil, MD, PhD, assistant professor of medicine and genetic medicine at Weill Cornell Medicine and cardiology consultant at the heart hospital Hamad Medical Corporation in Doha, Qatar.
Abi Khalil speculated that the results may point to a “blood pressure paradox,” which could be similar to a phenomenon known as the “obesity paradox,” in which patients with obesity and T2D have better survival that those without. Because this is an association and not a cause and effect, it’s been speculated that this may occur because these patients are followed more closely by physicians, and the same may be true of patients with heart failure and diabetes. The frequent follow-ups may suggest more care by cardiologists and diabetes specialists, along with early diagnosis of other health problems.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More